About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
R
Experts Discuss the Basics of GVHD
By
MyCancerHaven
FEATURING
Ravi Vij
,
Iskra Pusic
By
MyCancerHaven
FEATURING
Ravi Vij
,
Iskra Pusic
107 views
August 3, 2023
Click here to learn more about MyCancerHaven:
https://www.mycancerhaven.org/
0 Comments
Login to view comments.
Click here to Login
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
22:37
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlig…
Feat.
T. Badar
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
08:44
American Contact Dermatitis Society (ACDS)
What to Do When Patch Testing is Negative?
Feat.
M. Montanez-Wiscovich
12:47
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"
Feat.
S. O'Brien,
C. Coombs
17:05
Cleveland Clinic Taussig Cancer Institute
Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…
Feat.
A. Winter
13:07
Moffitt Cancer Center
R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?
Feat.
J. Chavez
04:16
Luke Fletcher
Efficacy and Safety of Asciminib in Ph+ CML
50:34
Scripps MD Anderson Cancer Center
The Cure of Leukemias in the Next Decade: An Optimist’s View
Feat.
H. Kantarjian
27:37
Indy Hematology Review
Review of Myeloproliferative Neoplasms
Feat.
A. Tefferi
09:18
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…
Feat.
J. Westin
18:04
Ruben Mesa
Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…
10:04
Tara Graff
How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…
06:53
UC Irvine Health
Fixed-Duration Treatment in CLL: Current Considerations
Feat.
E. Brem
11:12
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "SWOG S1826, a Randomized Study of Nivo-AV…
Feat.
A. Herrera
24:33
Indy Hematology Review
Therapeutic Options in CLL in 2023: Choosing the Initial Therapy Wis…
Feat.
J. Woyach
07:55
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes …
Feat.
E. Atallah
08:23
Total Health
R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment
Feat.
J. Chandler,
B. Randolph,
M. Onciu
08:18
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…
Feat.
A. Zhou
19:10
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center
Feat.
H. Kantarjian
08:17
Adam Kittai
Highlights From iwCLL 2023: What's New and Practice Informing i…
